<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">fcmedicine</journal-id><journal-title-group><journal-title xml:lang="ru">Фундаментальная и клиническая медицина</journal-title><trans-title-group xml:lang="en"><trans-title>Fundamental and Clinical Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2500-0764</issn><issn pub-type="epub">2542-0941</issn><publisher><publisher-name>КемГМУ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.23946/2500-0764-2022-7-4-91-99</article-id><article-id custom-type="elpub" pub-id-type="custom">fcmedicine-608</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Биохимические показатели крови у беременных женщин в норме и при хромосомной патологии плода</article-title><trans-title-group xml:lang="en"><trans-title>Serum biochemical parameters in pregnant women with and without fetal chromosomal abnornalities</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1169-715X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Волков</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Volkov</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Волков Алексей Николаевич, кандидат биологических наук, доцент кафедры биологии с основами генетики и паразитологии </p><p>650056, г. Кемерово, ул. Ворошилова, д. 22а</p></bio><bio xml:lang="en"><p>Dr. Alexey N. Volkov, PhD, Associate Professor, Department of Biology, Genetics, and Parasitology</p><p>22a, Voroshilova Street, Kemerovo, 650056</p></bio><email xlink:type="simple">volkov_alex@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2171-702X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рытенкова</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Rytenkova</surname><given-names>O. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рытенкова Оксана Ивановна, врач–лабораторный генетик медикогенетической лаборатории</p><p>650066, г. Кемерово, Октябрьский пр., д. 22</p></bio><bio xml:lang="en"><p>Mrs. Oksana I. Rytenkova, Geneticist, Medical Genetics Laboratory</p><p>22a, Voroshilova Street, Kemerovo, 650056</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6268-6242</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цуркан</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsurkan</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Цуркан Елена Владимировна, биолог медико-генетической лаборатории</p><p>650066, г. Кемерово, Октябрьский пр., д. 22</p></bio><bio xml:lang="en"><p>Mrs. Elena V. Tsurkan, Biologist, Medical Genetics Laboratory</p><p>22a, Voroshilova Street, Kemerovo, 650056</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6411-5112</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бабарыкина</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Babarykina</surname><given-names>T. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бабарыкина Татьяна Андреевна, фельдшер-лаборант медикогенетической лаборатории </p><p>650066, г. Кемерово, Октябрьский пр., д. 22</p><p> </p></bio><bio xml:lang="en"><p>Mrs. Tatiana A. Babarykina, Technician, Medical Genetics Laboratory</p><p>22a, Voroshilova Street, Kemerovo, 650056</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Суржикова</surname><given-names>Г. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Surzhikova</surname><given-names>G. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Суржикова Галина Северьевна, кандидат медицинских наук, заведующая кафедрой клинической лабораторной диагностики </p><p>654005, г. Новокузнецк, пр. Строителей, д. 5</p><p> </p></bio><bio xml:lang="en"><p>Dr. Galina S. Surzhikova, MD, PhD, Head of the Department of Clinical Laboratory Diagnostics</p><p>5, Stroiteley Prospekt, Novokuznetsk, 654005</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Кемеровский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kemerovo State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГАУЗ «Кузбасская областная клиническая больница» им. С.В. Беляева Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kuzbass Regional Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Новокузнецкий государственный институт усовершенствования врачей – филиал ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novokuznetsk State Institute for Postgraduate Education – Branch Russian Medical Academy for Postgraduate Education</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>29</day><month>12</month><year>2022</year></pub-date><volume>7</volume><issue>4</issue><fpage>91</fpage><lpage>99</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Волков А.Н., Рытенкова О.И., Цуркан Е.В., Бабарыкина Т.А., Суржикова Г.С., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Волков А.Н., Рытенкова О.И., Цуркан Е.В., Бабарыкина Т.А., Суржикова Г.С.</copyright-holder><copyright-holder xml:lang="en">Volkov A.N., Rytenkova O.I., Tsurkan E.V., Babarykina T.A., Surzhikova G.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://fcm.kemsmu.ru/jour/article/view/608">https://fcm.kemsmu.ru/jour/article/view/608</self-uri><abstract><sec><title>Цель</title><p>Цель. Анализ некоторых статистических характеристик, описывающих уровень сывороточных маркеров β-ХГЧ и РАРР-А в крови женщин, беременных плодом без хромосомных аномалий и при наличии у плода трисомии по 21-й или 18-й хромосомам.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проведен ретроспективный анализ биохимических показателей крови 1214 женщин, ранее проходивших обследования в рамках пренатального скрининга 1 триместра беременности. Все случаи были сгруппированы в зависимости от генетического статуса плода: с нормальным кариотипом, с трисомией по 21-й хромосоме, с трисомией по 18-й хромосоме.</p><p>Концентрации сывороточных маркеров β-ХГЧ и РАРР-А у обследуемых устанавливались с использованием автоматического анализатора AutoDELFIA. Цитогенетическое исследование проводилось пренатально (в случае высокого риска хромосомной патологии плода) и постнатально (при выявлении признаков хромосомной патологии у новорожденного). В ходе статистического анализа рассчитывались выборочные показатели. Сравнение групп проводилось с использованием непараметрических методов на основе расчета критерия χ2 после предварительной группировки данных. Отличия считали статистически значимыми при уровне p&lt;0,05. Силу установленных тенденций оценивали путем расчета величины отношения шансов с соответствующим 95% доверительным интервалом.</p></sec><sec><title>Результаты</title><p>Результаты. У большинства обследованных, имевших плод с трисомией-21, наблюдалось повышение содержания β-ХГЧ относительно нормы. При трисомии плода по 18-й хромосоме концентрация маркера в сыворотке крови беременной снижалась в 95,5% случаев. При хромосомной патологии плода уровень РАРР-А в крови беременных снижался относительно нормы. Так, доля образцов со сниженной вдвое концентрацией РАРР-А составила 52,4% и 88,6% в группах с трисомией-21 и трисомией-18 соответственно.</p></sec><sec><title>Заключение</title><p>Заключение. Уровень сывороточных маркеров b-ХГЧ и РАРР-А у беременных является чувствительным индикатором хромосомной патологии плода. При трисомии по 21-й хромосоме наблюдается повышение содержания b-ХГЧ и снижение уровня РАРР-А в крови пациентки. При трисомии плода по хромосоме 18 оба показателя демонстрируют тенденцию к снижению относительно нормы.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To analyse the levels of serum beta-human chorionic gonadotropin (β-hCG) and pregnancy-associated plasma protein A (PAPP-A) in pregnant women without fetal chromosomal abnormalities and with fetal trisomy 21 (Down syndrome) or 18 (Edwards syndrome).</p></sec><sec><title>Materials and Methods</title><p>Materials and Methods. We performed a retrospective analysis of serum biochemical parameters of 1214 women who had previously undergone karyotyping as a part of prenatal or postnatal screening. Patients were stratified into those with a normal fetal karyotype, those carrying a fetus with trisomy 21, and those carrying a fetus with trisomy 18. Levels of serum β-hCG and PAPP-A were estimated using the AutoDELFIA automatic immunoassay system.</p></sec><sec><title>Results</title><p>Results. In most of the women carrying a fetus with trisomy 21, serum β-hCG has been increased as compared to the reference range. In contrast, women carrying a fetus with trisomy 18 generally had reduced serum β-hCG. In both cases, the level of serum PAPP-A has been decreased in comparison with a reference range. The proportion of women with a 2-fold reduced serum PAPP-A was 52.4% and 88.6% if carrying fetuses with trisomy 21 and trisomy 18, respectively.</p></sec><sec><title>Conclusion</title><p>Conclusion. Serum b -hCG has been increased as compared to the reference range. In contrast, women carrying a fetus with trisomy 18 generally had reduced serum β-hCG. In both cases, the level of serum PAPP-A has been decreased in comparison with a reference range. The proportion of women with a 2-fold reduced serum PAPP-A was 52.4% and 88.6% if carrying fetuses with trisomy 21 and trisomy 18, respectively.</p></sec><sec><title>Conclusion</title><p>Conclusion. Serum b-hCG and PAPP-A are sensitive markers of fetal trisomy 21 and trisomy 18 in pregnant women.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>пренатальный скрининг</kwd><kwd>β-ХГЧ</kwd><kwd>РАРР-А</kwd><kwd>трисомия</kwd><kwd>цитогенетический анализ</kwd></kwd-group><kwd-group xml:lang="en"><kwd>prenatal screening</kwd><kwd>β-hCG</kwd><kwd>PAPP-A</kwd><kwd>trisomy</kwd><kwd>cytogenetic analysis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Филиппов О.С., Андреева Е.Н., Голошубов П.А., Калашникова Е.А., Одегова Н.О., Жученко Л.А. Современный пренатальный скрининг на врожденные пороки развития и хромосомные аномалии в Российской Федерации. Результаты Аудита-2017. Медицинская генетика. 2017;16(11):7-10.</mixed-citation><mixed-citation xml:lang="en">Filippov OS, Andreeva EN, Goloshubov PA, Kalashnikova EA, Odegova NO, Zhuchenko LA. Мodern prenatal screening for congenital malformations and chromosomal abnormalities in the Russian Federation. Results of the Audit-2017. Medical Genetics. 2017;16(11): 7-10. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Шавалиев Р.Ф., Яфарова С. Ш., Волгина С. Я. Профилактика редких болезней: современные аспекты и новые вызовы. Российский педиатрический журнал. 2017;20(4):226-232. http://dx.doi.org/10.18821/1560-9561-2017-20(4)–226-232</mixed-citation><mixed-citation xml:lang="en">Shavaliev RF, Yafarova SSh, Volgina SYa. Prevention of orphan diseases: contemporary aspects and new challenges. Russian Pediatric Journal. 2017;20(4):226-232. (In Russ). http://dx.doi. org/10.18821/1560-9561-2017-20(4)–226-232</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn. 2011;31(1):7-15. https://doi.org/10.1002/pd.2637</mixed-citation><mixed-citation xml:lang="en">Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn. 2011;31(1):7-15. https://doi.org/10.1002/pd.2637</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Goel N, Morris JK, Tucker D, de Walle HEK, Bakker MK. Trisomy 13 and 18 – prevalence and mortality – a multi-registry population based analysis. Am J Med Genet A. 2019;179(12):2382-2392. http://doi.org/10.1002/ajmg.a.61365</mixed-citation><mixed-citation xml:lang="en">Goel N, Morris JK, Tucker D, de Walle HEK, Bakker MK. Trisomy 13 and 18 – prevalence and mortality – a multi-registry population based analysis. Am J Med Genet A. 2019;179(12):2382-2392. http://doi.org/10.1002/ajmg.a.61365</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Волков А.Н., Рытенкова О.И. Цитогенетические методы в практике современных медико-биологических исследований. ЧАСТЬ III: числовые аномалии кариотипа человека. Фундаментальная и клиническая медицина. 2022;7(3):85-96. https://doi.org/10.23946/2500-0764-2022-7-3-85-96</mixed-citation><mixed-citation xml:lang="en">Volkov AN, Rytenkova OI. Cytogenetic techniques in current biomedical research. PART III: numerical alterations of human karyotype. Fundamental and Clinical Medicine. 2022;7(3):85-96. (In Russ). https://doi.org/10.23946/2500-0764-2022-7-3-85-96</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bull MJ. Down syndrome. N Engl J Med. 2020; 382(24):2344-2352. http://doi.org/10.1056/NEJMra1706537</mixed-citation><mixed-citation xml:lang="en">Bull MJ. Down syndrome. N Engl J Med. 2020; 382(24):23442352. http://doi.org/10.1056/NEJMra1706537</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Волков А.Н., Рытенкова О.И., Бабарыкина Т.А., Лысенко Д.И. Цитогенетическая диагностика хромосомных аномалий при неразвивающейся беременности. Клиническая лабораторная диагностика. 2017;62(9):553-556.</mixed-citation><mixed-citation xml:lang="en">Volkov AN, Rytenkova OI, Babarykina TA, Lysenko DI. The cytogenetic diagnostic of chromosome anomalies under non-developing pregnancy. Russian Clinical Laboratory Diagnostics. 2017;62(9):553-556. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Волков А.Н., Начева Л.В. Случай гипертриплоидии у абортуса при неразвивающейся беременности. Фундаментальная и клиническая медицина. 2020;5(1):99-102. https://doi.org/10.23946/25000764-2020-5-1-99-102</mixed-citation><mixed-citation xml:lang="en">Volkov AN, Nacheva LV. Нypertriploidy as a cause of early embryonic arrest. Fundamental and Clinical Medicine. 2020;5(1):99-102. (In Russ). https://doi.org/10.23946/2500-0764-2020-5-1-99-102</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides KH. First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing. Fetal Diagnosis and Therapy. 2014;35(2):118126. 1. Filippov OS, Andreeva EN, Goloshubov PA, Kalashnikova EA, Odegova NO, Zhuchenko LA. Мodern prenatal screening for congenital malformations and chromosomal abnormalities in the Russian Federation. Results of the Audit-2017. Medical Genetics. 2017;16(11): 7-10. (In Russ).</mixed-citation><mixed-citation xml:lang="en">Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides KH. First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing. Fetal Diagnosis and Therapy. 2014;35(2):118-126. 1. Filippov OS, Andreeva EN, Goloshubov PA, Kalashnikova EA, Odegova NO, Zhuchenko LA. Мodern prenatal screening for congenital malformations and chromosomal abnormalities in the Russian Federation. Results of the Audit-2017. Medical Genetics. 2017;16(11): 7-10. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Shavaliev RF, Yafarova SSh, Volgina SYa. Prevention of orphan diseases: contemporary aspects and new challenges. Russian Pediatric Journal. 2017;20(4):226-232. (In Russ). http://dx.doi.org/10.18821/1560-9561-2017-20(4)–226-232</mixed-citation><mixed-citation xml:lang="en">Shavaliev RF, Yafarova SSh, Volgina SYa. Prevention of orphan diseases: contemporary aspects and new challenges. Russian Pediatric Journal. 2017;20(4):226-232. (In Russ). http://dx.doi.org/10.18821/1560-9561-2017-20(4)–226-232</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn. 2011;31(1):7-15. https://doi.org/10.1002/pd.2637</mixed-citation><mixed-citation xml:lang="en">Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn. 2011;31(1):7-15. https://doi.org/10.1002/pd.2637</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Goel N, Morris JK, Tucker D, de Walle HEK, Bakker MK. Trisomy 13 and 18 – prevalence and mortality – a multi-registry population based analysis. Am J Med Genet A. 2019;179(12):2382-2392. http://doi.org/10.1002/ajmg.a.61365</mixed-citation><mixed-citation xml:lang="en">Goel N, Morris JK, Tucker D, de Walle HEK, Bakker MK. Trisomy 13 and 18 – prevalence and mortality – a multi-registry population based analysis. Am J Med Genet A. 2019;179(12):2382-2392. http://doi.org/10.1002/ajmg.a.61365</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Volkov AN, Rytenkova OI. Cytogenetic techniques in current biomedical research. PART III: numerical alterations of human karyotype. Fundamental and Clinical Medicine. 2022;7(3):85-96. (In Russ). https://doi.org/10.23946/2500-0764-2022-7-3-85-96</mixed-citation><mixed-citation xml:lang="en">Volkov AN, Rytenkova OI. Cytogenetic techniques in current biomedical research. PART III: numerical alterations of human karyotype. Fundamental and Clinical Medicine. 2022;7(3):85-96. (In Russ). https://doi.org/10.23946/2500-0764-2022-7-3-85-96</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bull MJ. Down syndrome. N Engl J Med. 2020; 382(24):23442352. http://doi.org/10.1056/NEJMra1706537</mixed-citation><mixed-citation xml:lang="en">Bull MJ. Down syndrome. N Engl J Med. 2020; 382(24):23442352. http://doi.org/10.1056/NEJMra1706537</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Volkov AN, Rytenkova OI, Babarykina TA, Lysenko DI. The cytogenetic diagnostic of chromosome anomalies under non-developing pregnancy. Russian Clinical Laboratory Diagnostics. 2017;62(9):553-556. (In Russ).</mixed-citation><mixed-citation xml:lang="en">Volkov AN, Rytenkova OI, Babarykina TA, Lysenko DI. The cytogenetic diagnostic of chromosome anomalies under non-developing pregnancy. Russian Clinical Laboratory Diagnostics. 2017;62(9):553-556. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Volkov AN, Nacheva LV. Нypertriploidy as a cause of early embryonic arrest. Fundamental and Clinical Medicine. 2020;5(1):99-102. (In Russ). https://doi.org/10.23946/2500-0764-2020-5-1-99-102</mixed-citation><mixed-citation xml:lang="en">Volkov AN, Nacheva LV. Нypertriploidy as a cause of early embryonic arrest. Fundamental and Clinical Medicine. 2020;5(1):99-102. (In Russ). https://doi.org/10.23946/2500-0764-2020-5-1-99-102</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides KH. First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing. Fetal Diagnosis and Therapy. 2014;35(2):118-126. doi:10.1159/000357430</mixed-citation><mixed-citation xml:lang="en">Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides KH. First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing. Fetal Diagnosis and Therapy. 2014;35(2):118-126. http://doi.org/10.1159/000357430</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Wald NJ, Bestwick JP, Huttly WJ. Improvements in antenatal screening for Down’s syndrome J Med Screen. 2013;20(1):7-14 http://doi.org/10.1177/0969141313476496</mixed-citation><mixed-citation xml:lang="en">Wald NJ, Bestwick JP, Huttly WJ. Improvements in antenatal screening for Down’s syndrome J Med Screen. 2013;20(1):7-14 http://doi.org/10.1177/0969141313476496</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kagan KO, Sonek J, Kozlowski P. Antenatal screening for chromosomal abnormalities. Arch Gynecol Obstet. 2022;305(4):825-835. http://doi.org/10.1007/s00404-022-06477-5</mixed-citation><mixed-citation xml:lang="en">Kagan KO, Sonek J, Kozlowski P. Antenatal screening for chromosomal abnormalities. Arch Gynecol Obstet. 2022;305(4):825-835. http://doi.org/10.1007/s00404-022-06477-5</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Donovan BM, Nidey NL, Jasper EA, Robinson JG, Bao W, Saftlas AF. First trimester prenatal screening biomarkers and gestational diabetes mellitus: A systematic review and meta-analysis. PLoS ONE. 2018;13(7):e0201319. https://doi.org/10.1371/journal.pone.0201319</mixed-citation><mixed-citation xml:lang="en">Donovan BM, Nidey NL, Jasper EA, Robinson JG, Bao W, Saftlas AF. First trimester prenatal screening biomarkers and gestational diabetes mellitus: A systematic review and meta-analysis. PLoS ONE. 2018;13(7):e0201319. https://doi.org/10.1371/journal.pone.0201319</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Huang T, Bedford HM, Rashid S, Rasasakaram E, Priston M, MakTam E, Gibbons C, Meschino WS, Cuckle H, Mei-Dan E. Modifi multiple marker aneuploidy screening as a primary screening test for preeclampsia. BMC Pregnancy Childbirth. 2022;22(1):190. https://doi.org/10.1186/s12884-022-04514-4</mixed-citation><mixed-citation xml:lang="en">Huang T, Bedford HM, Rashid S, Rasasakaram E, Priston M, MakTam E, Gibbons C, Meschino WS, Cuckle H, Mei-Dan E. Modifi multiple marker aneuploidy screening as a primary screening test for preeclampsia. BMC Pregnancy Childbirth. 2022;22(1):190. https://doi.org/10.1186/s12884-022-04514-4</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Antsaklis P, Fasoulakis Z, Theodora M. Association of low maternal pregnancy-associated plasma protein A with adverse perinatal outcome. Cureus. 2019;11(6):e4912. https://doi.org/10.7759/cureus.4912</mixed-citation><mixed-citation xml:lang="en">Antsaklis P, Fasoulakis Z, Theodora M. Association of low maternal pregnancy-associated plasma protein A with adverse perinatal outcome. Cureus. 2019;11(6):e4912. https://doi.org/10.7759/cureus.4912</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Luewan S, Teja-intr M, Sirichotiyakul S, Tongsong T Low maternal serum pregnancy-associated plasma protein-A as a risk factor of preeclampsia. Singapore Med J. 2018;59(1):55-59. doi: 10.11622/smedj.2017034</mixed-citation><mixed-citation xml:lang="en">Luewan S, Teja-intr M, Sirichotiyakul S, Tongsong T Low maternal serum pregnancy-associated plasma protein-A as a risk factor of preeclampsia. Singapore Med J. 2018;59(1):55-59. doi: 10.11622/smedj.2017034</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Wald NJ, Bestwick JP, Huttly WJ. Improvements in antenatal screening for Down’s syndrome J Med Screen. 2013;20(1):7-14 http://doi.org/10.1177/0969141313476496</mixed-citation><mixed-citation xml:lang="en">Wald NJ, Bestwick JP, Huttly WJ. Improvements in antenatal screening for Down’s syndrome J Med Screen. 2013;20(1):7-14 http://doi.org/10.1177/0969141313476496</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kagan KO, Sonek J, Kozlowski P. Antenatal screening for chromosomal abnormalities. Arch Gynecol Obstet. 2022;305(4):825-835. http://doi.org/10.1007/s00404-022-06477-5</mixed-citation><mixed-citation xml:lang="en">Kagan KO, Sonek J, Kozlowski P. Antenatal screening for chromosomal abnormalities. Arch Gynecol Obstet. 2022;305(4):825-835. http://doi.org/10.1007/s00404-022-06477-5</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Donovan BM, Nidey NL, Jasper EA, Robinson JG, Bao W, Saftlas AF. First trimester prenatal screening biomarkers and gestational diabetes mellitus: A systematic review and meta-analysis. PLoS ONE. 2018;13(7):e0201319. https://doi.org/10.1371/journal.pone.0201319</mixed-citation><mixed-citation xml:lang="en">Donovan BM, Nidey NL, Jasper EA, Robinson JG, Bao W, Saftlas AF. First trimester prenatal screening biomarkers and gestational diabetes mellitus: A systematic review and meta-analysis. PLoS ONE. 2018;13(7):e0201319. https://doi.org/10.1371/journal.pone.0201319</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Huang T, Bedford HM, Rashid S, Rasasakaram E, Priston M, MakTam E, Gibbons C, Meschino WS, Cuckle H, Mei-Dan E. Modifi multiple marker aneuploidy screening as a primary screening test for preeclampsia. BMC Pregnancy Childbirth. 2022;22(1):190. https://doi.org/10.1186/s12884-022-04514-4</mixed-citation><mixed-citation xml:lang="en">Huang T, Bedford HM, Rashid S, Rasasakaram E, Priston M, MakTam E, Gibbons C, Meschino WS, Cuckle H, Mei-Dan E. Modifi multiple marker aneuploidy screening as a primary screening test for preeclampsia. BMC Pregnancy Childbirth. 2022;22(1):190. https://doi.org/10.1186/s12884-022-04514-4</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Antsaklis P, Fasoulakis Z, Theodora M. Association of low maternal pregnancy-associated plasma protein A with adverse perinatal outcome. Cureus. 2019;11(6):e4912. https://doi.org/10.7759/cureus.4912</mixed-citation><mixed-citation xml:lang="en">Antsaklis P, Fasoulakis Z, Theodora M. Association of low maternal pregnancy-associated plasma protein A with adverse perinatal outcome. Cureus. 2019;11(6):e4912. https://doi.org/10.7759/cureus.4912</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Luewan S, Teja-intr M, Sirichotiyakul S, Tongsong T Low maternal serum pregnancy-associated plasma protein-A as a risk factor of preeclampsia. Singapore Med J. 2018;59(1):55-59. https://doi.org/10.11622/smedj.2017034</mixed-citation><mixed-citation xml:lang="en">Luewan S, Teja-intr M, Sirichotiyakul S, Tongsong T Low maternal serum pregnancy-associated plasma protein-A as a risk factor of preeclampsia. Singapore Med J. 2018;59(1):55-59. doi: 10.11622/smedj.2017034</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
